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Key Points 
● Studies achieved an average Radiomics Quality Score of 10.8%. Common reasons for low 
Radiomics Quality Scores were unvalidated results, retrospective study design, absence of open 
science and insufficient control for multiple comparisons. 
● A previous training phase allowed reaching almost perfect inter-rater agreement in the 
application of the Radiomics Quality Score. 
● Meta-analysis of radiomics studies distinguishing angiomyolipoma without visible fat from renal 
cell carcinoma show moderate diagnostic odds ratios of 6.24 and moderate methodological 
diversity. Abbreviations 
Abbreviations 
AMLwvf: Angiomyolipoma without visible fat 
ICC: Interrater Correlation Coefficient 
ML: Machine Learning 
RCC: Renal Cell Carcinoma 
RQS: Radiomics Quality Score 
QUADAS: Quality Assessment of Diagnostic Accuracy Studies 
  
Abstract 
Objectives: (1) To assess the methodological quality of radiomics studies investigating histological 
subtypes, therapy response and survival in patients with renal cell carcinoma (RCC) and (2) to determine 
the risk of bias in these radiomics studies. 
Methods: In this systematic review, literature published since 2000 on radiomics in RCC was included 
and assessed for methodological quality using the Radiomics Quality Score. The risk of bias was assessed 
using the Quality Assessment of Diagnostic Accuracy Studies tool and a meta-analysis of radiomics 
studies focusing on differentiating between angiomyolipoma without visible fat and RCC was performed. 
Results: Fifty-seven studies investigating the use of radiomics in renal cancer were identified, including 
4590 patients in total. The average Radiomics Quality Score was 3.41 (9.4% of total) with good inter-rater 
agreement (ICC:0.96, 95%-CI:0.93-0.98). Three studies validated results with an independent dataset, 
one used a publically available validation dataset. None of the studies shared the code, images or 
regions-of-interest. The meta-analysis showed moderate heterogeneity among the included studies and 
an odds ratio of 6.24 (95%-CI:4.27–9.12; p<0.001) for the differentiation of angiomyolipoma without 
visible fat from RCC. 
Conclusions: Radiomics algorithms show promise for answering clinical questions where subjective 
interpretation is challenging or not established. However, the generalizability of findings to prospective 
cohorts needs to be demonstrated in future trials for progression towards clinical translation. Improved 
sharing of methods including code and images could facilitate independent validation of radiomics 
signatures. 
Introduction 
Radiological practice relies largely on the subjective interpretation of imaging data by an expert 
radiologist. Reports will therefore be dependent on reader experience. Quantitative, reader independent 
imaging markers may supplement expert opinion and increase diagnostic, predictive and prognostic 
accuracy [1]. Radiomics includes a number of strategies aimed at converting medical images to 
quantitative, minable, high-dimensional data. These include histogram, texture and shape analysis, that 
extract information from imaging data which may not be visible to the human eye [2, 3]. In recent years, 
increased interest in the use of radiomics in oncological imaging has led to its application as a tool to 
derive diagnostic, predictive and prognostic information from routine clinical imaging [4]. Despite 
extensive use in research and reports linking CT and MR texture to lesion characterization, survival and 
perioperative outcome in a number of malignancies, translation into clinical practice has not yet 
occurred [5]. 
Renal cell carcinoma (RCC) is newly diagnosed in 338,000 patients annually worldwide and incidence 
varies widely with the highest incidence in Northern America, Europe, Australia and New Zealand [6]. 
Most countries have seen a rise in incidence over the past decades, which has been attributed to the 
increasing use of cross-sectional imaging and subsequent incidental diagnosis [7]. Increasing diagnosis of 
small renal masses carries the risk of overtreatment resulting in benign histology in 10% - 30% of all 
resected tumors [8, 9]. While CT is the mainstay of diagnostic imaging in RCC, MRI has become a valuable 
problem-solving tool. Owing to its improved soft-tissue-contrast, MRI outperforms CT in the evaluation 
of indeterminate cystic masses (Bosniak 2F and 3, malignancy in 10% and 50% respectively) [10], local 
invasion and intra-vascular extension [11]. Still, the differentiation of benign renal lesions, especially 
oncocytoma and angiomyolipoma without visible fat (AMLwvf), from RCC can be challenging by 
subjective radiological image interpretation [12]. Quantitative image analysis may reveal radiomic 
signatures diagnostic of renal tumor subtype and aggressiveness or predictive of response to targeted 
treatment, therefore, aiding treatment stratification. However, for imaging markers including texture-
based metrics to cross the translational gap between an exploratory research tool and a clinically 
applicable diagnostic algorithm, technical validity, biological validity, qualification, and cost-effectiveness 
need to be established (Figure 1) [13]. 
This systematic review aims to establish whether the methodological quality of prospective and 
retrospective studies published on radiomics in cross-sectional imaging of renal tumors for diagnostic, 
predictive and prognostic purposes poses barriers to effective clinical translation. A meta-analysis of the 
use of texture-based models for the discrimination of AMLwvf and RCC shall assess the ability of 
proposed models to answer this clinically relevant question. 
Methods 
This systematic review was conducted according to the PRISMA-DTA (Preferred Reporting Items for 
Systematic Reviews and Meta-Analysis for Diagnostic Test Accuracy) statement [14]. The review protocol 
is available through PROSPERO (CRD 42018115263). The electronic databases PubMed, EMBASE and 
Web of Science were searched for primary publications in English assessing texture analysis in RCC in CT 
or MRI published after 01/01/2000. The databases were last searched on the 30/10/2018. The search 
term consisted of (textural OR radiomics OR texture OR histogram) AND (kidney OR renal) AND 
(“computed tomography” OR CT or “magnetic resonance” OR MRI OR MR). 
A single researcher with two years of post-graduate experience in medical image analysis (SU) screened 
titles and abstracts to determine eligibility. Articles in which texture analysis was employed for 
diagnostic, predictive or prognostic purposes on CT or MR images of RCC were obtained in full for further 
evaluation. Contact with the authors was sought if the full-text version was not accessible otherwise. 
Studies were excluded if they were case reports, conference abstracts or short communications because 
they do not provide sufficient information to assess the methodological quality. The reference lists of 
included studies were screened for additional, potentially eligible articles. Uncertainties were resolved in 
consensus between SU, LB and AB 
The Radiomics Quality Score (RQS) and the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-
2) were used to assess the methodological quality of the included studies and the risk of bias on the 
study level, respectively [15, 16]. The RQS is a recently proposed tool to measure the methodological 
rigor of radiomics studies. It interrogates image acquisition, radiomics features extraction, data 
modelling, model validation, and data sharing. Each of the 16 dimensions (Table 1) of the score is rated 
resulting in a sum of points ranging from -8 to 36 with -8 – 0 defined as 0% and 36 defined as 100% [15]. 
The QUADAS-2 tool assesses the presence of bias in the domains of “patient selection”, “index test”, 
“reference standard” and “flow and timing”. The tool can be tailored to the specific research question 
through signaling questions for risks of bias which are specific to the individual research question [16]. 
During a training phase, the three reviewers (doctoral student with 2 years of postgraduate experience 
in medical image analysis (SU), a radiologist in the 4th year of training (LB) and a board-certified 
radiologist with 8 years of experience (AB)) independently extracted study data from two randomly 
chosen articles into a structured data collection instrument generated based on RQS and QUADAS-2. 
Disagreements were discussed in order to achieve a shared understanding of each parameter. 
Subsequently, at least two raters assessed and rated each study independently and recorded these on 
the data collection instrument. The data collection instrument can be found in supplementary Table S1. 
Statistical analysis was conducted using R language for statistical computing [17]. Analyses were 
performed using the metafor, irr and raters packages [18]. Unless otherwise specified, the average rating 
of all raters is reported. Interrater agreement for single items of the RQS was calculated using a modified 
Fleiss kappa statistic for ordinal variables [19]. A 95% confidence interval was derived from a Monte 
Carlo test and bootstrap procedure over 1000 iterations. P-values for the null-hypothesis that agreement 
resulted from chance alone were calculated. The interclass correlation coefficient (ICC) was determined 
to describe interrater agreement for the summed RQS using a single source, two-way random effects 
model determining absolute agreement between raters. 
As pre-defined in the review protocol, studies would be included in a meta-analysis of a large enough 
subset of the included studies if a similar clinical question was assessed repeatedly. Upon review of the 
study population, the differentiation of lesions defined as either fat poor AML, AMLwvf or AML without 
macroscopic fat from malignant renal tumors was addressed repeatedly. These studies were included in 
the meta-analysis. Two-by-two contingency tables were extracted or reconstructed and odds ratios were 
calculated as effect size. A random-effects model was used to calculate the summary effect size. If 
multiple texture models were reported in a study, only the one with the highest area under the receiver 
operating curve or the highest Youden’s J statistic, if no AUC was reported, was included. If data 
augmentation, the generation of new data through random transformation of existing cases, was 
performed, the augmented cases were not included in the meta-analysis. A funnel plot was constructed 
to visually assess the risk of publication bias and the trim and fill method was used to estimate the 
number of missing studies. Q and I2 were calculated to estimate the heterogeneity among the studies 
included in the meta-analysis. A more detailed description of the statistical methods can be found in the 
supplementary materials. 
Results 
The initial search yielded 776 articles of which 263 were duplicates. Of the remaining 513, 454 were 
rejected based on title and abstract. Of the 59 full-text manuscripts retrieved, 57 were included in the 
systematic review (Figure 2). The articles employed radiomics-based diagnostic models to assess similar 
clinical questions repeatedly. The differentiation of benign and malignant lesions was investigated by 
39% (22/57) of the articles while 27% (15/57) explored subtype differentiation and 21% (12/57) 
interrogated treatment response/outcome prediction. Tables S2 and S3 summarize study aims and 
characteristics, respectively. 
The 57 studies reached a mean ± standard deviation RQS of 3.41±4.43, median 4.5, interquartile range: 
6.17, range: -4.0-16.6. The average percentage RQS was 9.4% with a maximum of 46%. The average 
rating for each dimension is summarized in Table 1, the RQS for individual studies and individual ratings 
for each study are presented in Tables S2 and S4 respectively. Most studies applied discrimination 
statistics, included biological correlates and addressed their potential clinical utility. Conversely, none of 
the studies included in this systematic review employed phantoms or assessed the cost effectiveness of 
radiomics-based decision support systems. No study shared either segmentations or code publicly and 
only few assessed the repeatability of radiomics analysis at multiple time points, employed calibration 
statistics or a validation cohort. Only 39% (22/57) of the studies segmented the entire 3D tumor volume 
for texture analysis, and 91% (52/57) used manual segmentation. Inter-reader agreement was assessed 
in 32% (18/57) of the studies and found to be moderate to excellent for single features or radiomics 
signatures. Only a single study investigated the repeatability of radiomics measurements and found poor 
to good repeatability of histogram parameters of the transfer constant of dynamic contrast-enhanced 
MRI [20]. 
Studies included in this review extracted between four and 18,720 features (median 24) from two to 249 
patients (median 61). The ratio between features and patients ranged from 25 times more patients than 
features to 240 times more features than patients (median of 2.2-times more patients than features). 
Feature reduction or adjustment for multiple testing was used in 51% of studies (29/57) and while 14% 
(8/57) relied on prospectively acquired data, none included plans for radiomics analysis in its prospective 
registration. Validation of radiomics signatures on independent validation datasets was performed in 5% 
(3/57) of the studies, only one of which employed an external dataset.  
Assessment of the studies with the QUADAS-2 tool revealed methodological aspects increasing the risk 
of bias. As QUADAS-2 is not intended as a quantitative score, concern of bias from the reviewers was 
aggregated qualitatively for the different dimensions addressed by the tool (Table S5). Risk factors for 
bias which were repeatedly identified are summarized in Figure 3. Risk factors relating to patient 
selection and timing of index and reference tests were particularly frequently observed. Reporting the 
temporal delay between the index and reference test may be critical when determining tumor nuclear 
grade which influences progression and less critical when comparing RCC histological subtypes. The 
heavy reliance of literature on radiomics in RCC on retrospective surgical cohorts scanned with multiple 
scanners risks sampling technically variable data. Most studies explained texture feature extraction in 
detail; however, machine learning based models were employed in many papers without sufficient 
description of the model parameters to allow replication. 
The reproducibility of the RQS and QUADAS-2 was also assessed. During the training phase, particular 
variability in the rating of the detection and discussion of biological correlates was identified. The 
reviewers agreed to rate the item more liberally in agreement with previous publications [21]. The ICC 
for the RQS was 0.96 (95%-CI:0.93-0.98). The ICC for studies rated by all three reviewers (11/57) was 
0.92 (95%-CI:0.80-0.98). Substantial or almost perfect agreement was achieved for most individual 
elements of the RQS. Only moderate agreement was reached in the assessment of the imaging protocol 
(Table 2). Absolute agreement concerning risk of bias and applicability of the seven indicator questions 
of the QUADAS tool was generally above 75% for most dimensions. Absolute agreement was 58% in the 
assessment of the risk of selection bias. 
Publication bias is a concern in radiomics studies in particular. Indeed, only 4/57 (7%) publications 
included in this review report non-significant outcomes, all analyzing the differentiation of AML and RCC. 
In the absence of prospective investigations with predefined study protocols, selective reporting of 
positive outcomes is a risk. 
Thirteen of the 57 studies (23%) discussed the use of radiomics for the differentiation of AMLwvf and 
malignant renal tumors. Of these, 77% (10/13) provided information to reconstruct a contingency table 
and calculate the effect size and were included in the meta-analysis. The summary effect size under the 
random effects model across the studies indicated a diagnostic odds ratio of 5.89 (95% CI: 4.02-8.23 
p<.001) for radiomics models differentiating AMLwvf from RCC (Figure 4). Cochran’s Q of 13.41, p=.15 
with 9 degrees of freedom and I2=33.5% suggested the presence of moderate study-to-study dispersion. 
The funnel plot relating effect size to its standard error is shown in Figure 5. Trim and fill analysis 
estimated that one study on the left side was missing. Following the addition of this study, the estimated 
overall effect size is OR=5.55 (95% CI: 3.77-8.16, p<0.001). Considerable diversity existed among the 
radiomics features calculated and only mean in the unenhanced, entropy in the unenhanced and 
nephrographic phase CT were found to differentiate AMLwvf and RCC in two studies. Two studies 
assessing the ability of low attenuation voxel percentage to differentiate AMLwvf and RCC found 
significant differences in opposing directions [22, 23]. 
Discussion 
Radiomics may provide new quantitative imaging markers without the need to invest in new acquisition 
equipment or tracers. Multiple studies have shown promise in answering clinical questions that 
conventional, qualitative radiological diagnosis cannot answer. However, none of the multifactorial 
radiomics algorithms has achieved clinical translation or been independently validated. This systematic 
review has identified several common characteristics among the included studies that hinder rapid 
adoption of proposed algorithms into the clinic. Replication and independent validation of research 
findings relies on sharing of imaging data, segmentations and code. None of the studies included in this 
review have provided open access to the code employed for data preparation, feature extraction and 
model construction. This is particularly crucial where image pre-processing and artificial intelligence 
based modeling were applied. Guidelines recommending reporting standards for machine learning (ML) 
models have been published, however, making the code used for data analysis publically available would 
be preferable [24]. Overall, 34/57 studies used ML models. There was a trend for these studies to be 
more recent than those not using any ML models. Furthermore, studies incorporating ML algorithms 
achieved significantly higher RQS ratings than studies without (5.16 ± 3.66 vs. 0.83 ± 4.27, p < .001). This 
was due, in particular, to less frequent validation of results, inclusion of non-radiomics parameters and 
use of feature reduction and correction for multiple comparisons in non-ML studies. 
Where patient numbers are limited and countless radiomics features can be quantified, it is critical to 
reduce the feature space, e.g. through removal of poorly reproducible features to reduce the risk of 
overfitting. This could be achieved with texture phantoms that were not employed by any of the studies 
in this review. Furthermore, appropriate statistical correction for multiple comparisons and independent 
validation, which has only been applied very rarely among the included studies, will reduce the risk of 
false positive and overly optimistic results. Meanwhile, prospective trials, where hypotheses are defined 
in advance, reduce the risk of reporting bias. Most trials included in this review only assessed surgical 
patients. However, surgical cohorts may be enriched in malignant lesions and larger tumor sizes, leading 
to selection bias. Small renal masses, which can be difficult to classify, may be assigned to active 
surveillance and are, therefore, underrepresented in surgical cohorts. 
The RQS has been proposed to assess the methodological quality of radiomics studies, which is 
important to critically appraise the large number of publications and to prioritize validation of high 
quality results. Because varying interrater agreement was observed in the first application of the RQS 
[21], two articles were used to train researchers. As a result, high agreement for the overall rating (ICC = 
0.96) and most elements of the score (S* > 0.75) was achieved. Compared to the first application of the 
RQS, the average RQS rating was lower (10.8% vs 21.9%) as was the rating for the best performing study 
(48% vs 55.5%). Another, recently published review employing the RQS did not report interrater 
agreement [25].Only few systematic reviews in radiomics literature have been published and even fewer 
assessed methodological quality systematically and quantitatively As a result, the RQS has not yet found 
widespread application. 
The dependency of multiple radiomics features on image acquisition parameters has been demonstrated 
repeatedly [26–28]. However, only half of the studies included in this review, documented the most 
important parameters. The selection of the scanner manufacturer and model, acquisition and 
reconstruction parameters cause heterogeneity of imaging data. If the aim is to achieve broadly 
applicable radiomics models, standardization will be required wherever possible. Elsewhere, feature 
selection could consider robustness to variations in acquisition parameters and adjustments could be 
applied to the input data or the extracted features. The non-quantitative nature of T1 and T2-weighted 
MR sequences introduces additional heterogeneity even when acquisition parameters are kept constant. 
As a result, MR-based radiomics models frequently employed parametric maps, which do not require 
initial signal intensity normalization, were used most commonly. Out of 17 studies using MR, nine 
included the advanced diffusion coefficient based on diffusion-weighted imaging and two the transfer 
constant kTrans from dynamic contrast-enhanced MRI in their analysis. Two studies employed ADC 
histogram parameters to differentiate tumor subtypes observing similar trends but differential statistical 
significance due to low numbers of cases. 
 
Most studies segmented only part of the tumor. In light of recent findings highlighting the intratumoral 
heterogeneity in RCC on a genetic and metabolic level, texture analysis in a single 2D slice risks 
underestimating intratumoral heterogeneity [29–31]. However, studies segmenting single 2D slices of 
the tumor achieved equal RQS ratings and no trend over time favoring one segmentation strategy was 
apparent. The few publications comparing 2D and 3D texture analysis reached varying conclusions 
regarding their ability to correctly measure heterogeneity in tumors. However, it seems premature to 
suggest that segmentation of single slices was equivalent in diagnostic value to segmentation of an 
entire lesion. Only a small subset of the studies (5/57) placed small regions of interest within the tumor. 
These were either very early studies or studies where multiregional tissue sampling to match the regions 
of interest was carried out. Additionally, there is scope for further integration of radiomics data with 
clinical, genetic and metabolic data to achieve a more complete understanding of renal cancer and 
harness the complementary value of each modality in cancer diagnostics, prognosis, treatment response 
prediction and monitoring. 
This review has some inherent limitations. First, the articles included in the meta-analysis differed 
slightly in their inclusion criteria. The control group was composed of ccRCC only in four studies while six 
included RCC of multiple subtypes. The methodology will always differ between radiomics studies as 
different centers use different equipment and the choice of image reconstruction, filtration, feature 
extraction and calculation of radiomics models offer countless combinations. Still, a meta-analysis of the 
existing evidence provides important information as to the consistency of results and the magnitude of 
the effect size that can be anticipated and helps to estimate publication bias. Notably, the clinically more 
relevant question of differentiating oncocytoma from RCC was less frequently assessed. A number of 
studies included in this review were published before the introduction of the RQS. However, there was 
no trend for improvement over time, therefore this was not thought to be a significant risk of bias. The 
RQS as well as QUADAS-2 have limitations. While the former is a quantitative metric and a debate about 
the appropriate weighting of different components is justified, the latter is a qualitative score and 
therefore less easily interpretable. Still, both scores are timely tools for the assessment of 
methodological quality of this highly specialized area of research. 
In conclusion, radiomics models show promise for augmenting radiological diagnosis in renal cancer. The 
differentiation of AMLwvf and RCC has been investigated repeatedly and a meta-analysis showed 
moderate ability of radiomics to facilitate this distinction. However, well-designed and appropriately 
powered prospective radiomics trials are needed for these novel imaging markers to demonstrate their 
validity and progress towards clinical translation. 
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Figure 1: Pathway for the development of radiomics algorithms and challenges in clinical translation. In 
addition to image acquisition and image registration, non-quantitative MRI sequences may undergo 
intensity normalization to improve intra- and inter-patient heterogeneity. Subsequently, either classical 
machine learning algorithms or deep learning are employed to define diagnostic, prognostic or predictive 
models. These models require external validation, ensuring transferability of results between sites and 
MR-scanners before prospective validation and demonstration of cost-effectiveness can enable these 
diagnostic support systems to enter clinical practice. Continuous monitoring is required to detect 
deteriorating model performance as image acquisition evolves to trigger re-training and model update. 
ANN: Artificial Neural Network 
Figure 2: Study selection flowchart. 
Figure 3: Risk factors for bias colored according the four dimensions of the QUADAS tool. The length of 
the bars is equivalent to the frequency with which this risk factor was identified among the included 
studies. 
Figure 4: Forrest plot of the effect size calculated as log odds ratio for 10 of 13 studies investigating the 
diagnostic accuracy of radiomics in the differentiation of AMLwvf from RCC. TP: Number of AMLwvf 
patients correctly diagnosed, FN Number of AMLwvf patients diagnosed as having RCC. FP Number of 
RCC patients diagnosed as having AML, TN number of RCC patients correctly diagnosed. X-axis: log-
transformed odds ratios, RE: random effects 
Figure 5: Funnel plot of studies included in the meta-analysis (black) and missing studies identified by 
trim and fill analysis (white dot). The funnel plot was asymmetric with more studies than expected 
reporting higher odds ratios for the ability of radiomics to differentiate between malignant renal tumors 
and benign AMLwvf, this can indicate the presence of publication bias. 
 
Table legends 
Table 1 Elements of the RQS as described by Lambin et.al. [15] and average rating achieved by the 
studies included in this systematic review. 




























+1 if segmented multiple times (different physicians, algorithms 
or perturbation of regions of interest) 
0.38 
Phantom Study 





+1 multiple timepoints for feature robustness assessment 0.01 
Feature 
Reduction 
-3 if nothing, +3 if either feature reduction or correction for 
multiple testing 
0.23 
Non Radiomics +1 if multivariable analysis with non-radiomics features 0.15 
Biological 
Correlates 
+1 if present 0.98 
Cut-off 





+1 for discrimination statistic and statistical significance, +1 if 
resampling applied 
0.92 
Calibration +1 for calibration statistic and statistical significance 0.04 
Prospective +7 for prospective validation within a registered study 0.98 
Validation 
-5 if no validation / +2 for internal validation / +3 for external 
validation / +4 two external validation datasets or validation of 
previously published signature / +5 validation on ≥3 datasets 
from >1 institute 
-4.61 
Gold Standard +2 for comparison to gold standard 1.73 
Clinical Utility +2 for reporting potential clinical utility 1.91 
Cost-
effectiveness 
+1 for cost-effectiveness analysis 0.00 
Open Science 
+1 for open source scans, +1 for open source segmentations, +1 
for open source code, +1 open source representative 
segmentations and features 
0.02 




RQS Scoring Item S* [95% CI] 
Image Protocol 0.45 [0.20 – 0.67] 
Multiple Segmentations 0.93 [0.82 – 1.00] 
Phantom Study 1.00 [1.00 – 1.00] 
Multiple Time Points 0.93 [0.82 – 1.00] 
Feature Reduction 0.93 [0.82 – 1.00] 
Non Radiomics 0.67 [0.49 – 0.85] 
Biological Correlates 0.93 [0.82 – 1.00] 
Cut-off 0.93 [0.82 – 1.00] 
Discrimination and Resampling 0.82 [0.71 – 0.92] 
Calibration 0.96 [0.89 – 1.00] 
Prospective 1.00 [1.00 – 1.00] 
Validation 1.00 [1.00 – 1.00] 
Gold Standard 0.76 [0.63 – 0.88] 
Clinical Utility 0.60 [0.38 – 0.82] 
Cost-effectiveness 1.00 [1.00 – 1.00] 
Open Science 1.00 [1.00 – 1.00] 
CI: Confidence Interval, RQS: Radiomics Quality Score 
 
